U.S.-listed biotech companies are increasingly reliant on innovations from China, with an estimated one-third of industry licensing spending in 2025 directed toward drugs developed overseas. This shift is particularly pronounced in antibody-drug conjugates (ADCs), where Chinese firms account for nearly 90% of global licensing activity. As U.S. biotech firms like Summit Therapeutics (SMMT) license foreign-developed therapies, investors face new risks, particularly regarding the regulatory acceptance of clinical trial data from diverse populations.

The implications for the financial markets are significant. Summit’s reliance on the Chinese-developed ivonescimab has led to disappointing outcomes in U.S. trials, contributing to a 35% decline in its stock over the past year. Major pharmaceutical companies, such as Merck, are also vulnerable as they increasingly depend on Chinese innovations. The FDA’s scrutiny of foreign data could hinder approval processes, raising concerns about the sustainability of these licensing strategies.

Investors should carefully evaluate the origins of a biotech company’s assets before investing. Firms that develop their own drugs may warrant higher valuations, while those that rely heavily on licensed candidates face additional risks, including regulatory hurdles and potential royalty obligations. Understanding these dynamics is crucial for navigating the evolving biotech landscape.

Source: fool.com